Navigation Links
Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO
Date:6/2/2008

Data Show Activity in First- and Late-Line Treatment of NSCLC

CHICAGO, June 2 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) reported data from three clinical trials of XL647, a novel small molecule inhibitor of EGFR, HER2, and VEGFR2, at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). Updated data from an ongoing phase 2 trial in previously untreated, clinically selected non-small cell lung cancer (NSCLC) patients show encouraging anti-tumor activity of XL647 administered on an intermittent dosing schedule or a continuous daily dosing schedule. Additionally, data from a phase 2 trial in patients who progressed after prior benefit from erlotinib or gefitinib, or who have a documented EGFR-T790M mutation, also show encouraging signs of activity of XL647 in this heavily pretreated population. Furthermore, XL647 was generally well tolerated and showed favorable exposure and tolerability profiles in a phase 1 trial evaluating daily dosing in patients with advanced solid tumors.

Phase 2 Trial of XL647 in Clinically Selected NSCLC Patients Enriched for the Presence of EGFR Mutations

In this trial, patients with NSCLC were clinically selected on the basis of adenocarcinoma histology, and either having a documented EGFR activating mutation in their tumor, or meeting one of the following criteria: Asian, female, or minimal smoking history. Approximately 30% of the patients analyzed had EGFR activating mutations. A total of 41 patients were treated with 350 mg of XL647 on an intermittent (5 days on/9 days off) dosing schedule, while 8 patients were treated with 300 mg of XL647 on a daily dosing schedule.

Consistent with data from this phase 2 trial reported in October 2007 at the
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Exelixis Commences Public Offering of Common Stock
2. Exelixis Announces September 18 Webcast of Presentation at the Bank of America 2007 Investment Conference
3. Exelixis Announces October 10 Webcast of Presentation at the 2007 Bio InvestorForum Conference
4. Exelixis Announces November 6 Webcast of Presentation at the CIBC World Markets 18th Annual Healthcare Conference
5. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
6. Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction With The American Society of Hematology 48th Annual Meeting
7. Reminder: Exelixis Announces December 10 Webcast of Its Analyst and Investor Briefing in Conjunction with The American Society Of Hematology 48th Annual Meeting
8. Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
(Date:10/20/2014)... WA (PRWEB) October 20, 2014 My ... workflow management software application. The new module enables ... patients receive full life-cycle quality care. , This application ... others within their practice, attach a to-do item to ... fit, and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... 2014 Based on a proprietary ... imaging assays capable of determining DNA sequence, location ... these three dimensions of high-resolution data, dGH assays ... widest range of disease-causing genetic rearrangements, including chromosomal ... genomic tools, including today’s advanced sequencing technologies. , ...
(Date:10/20/2014)... Cleveland, Ohio (PRWEB) October 20, 2014 Unveiled ... Affairs’ new Strategic Direction Scorecard conservatively estimates member hospital ROI ... dollar spent on dues, The Center provides $12.50 in value ... ROI is (Member Value – Member Dues)/Member Dues. , ... get at this number and we think the methodology is ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... A new approach of imaging discovered by scientists now detects even small smoking-related lung ... track deep into the smokers lungs and its movement - researchers at the University ... images of lungs soft tissues, when helium gas was inhaled prior taking images. ... ...
... anti-quota strike, setting the stage for a face-off with the ... the 19-day long protest can invite contempt proceedings. ... General Body Meetings of the medicos which saw sharp divisions ... has paralysed medical services in the capital., ,'The Youth ...
... incidence of HIV/AIDS is declining in the western Indian state ... , Karnataka and Andhra Pradesh because of the proactive measures ... in the country, especially in the north, it is rising, ... released Tuesday, said that overall two-thirds of the people living ...
... Court of India today asked the students to end their ... if they fail to do so contempt// action can be ... told that their protest had left "patients at the mercy ... are continuing with the strike. If they are over-reaching our ...
... Myanmar into India's northeast has led to a rise in ... says a United Nations study. ,"Drug trafficking across the ... Mizoram and Nagaland occurs with ease. Despite the existence of ... accessible to the local youths of these states," said a ...
... planning to study the effect of cervical cancer on the ... as the biggest study into the psychological and emotional effects ... will be instituted for duration of five years and will ... physical lives of couples. The researchers have said that they ...
Cached Medicine News:Health News:Helium And MRI Scanning Clearly Detects Smoker Lungs – Research Find 2Health News:Supreme Court Warns Medicos of Contempt Action 2Health News:Illegal Drug Trafficking Pose A Great Threat For HIV Epidemic In Northeast 2
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
(Date:10/19/2014)... -- Shire plc (LSE: SHP, NASDAQ: SHPG ... (CFO), has notified the Board of Directors of his decision to ... opportunity as CFO of Severn Trent plc.  James will leave Shire ... a search for a new CFO immediately. Flemming Ornskov, ... and lead a high-quality finance team at Shire. We are very ...
Breaking Medicine Technology:ResMed Launches ResMed Data Exchange 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... GlySure Limited, developer of in-hospital continuous ... its $10.9 million Series C financing round. GlySure will ... approval in the United States and Europe. ... well as existing investors Amadeus Capital Partners, Chester Investments ...
... -- Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ... integrated pharmaceutical company engaged in the distribution of ... herbal cultivation and sales in China through its ... today announced the appointment of Mr. Kwong Chi ...
Cached Medicine Technology:GlySure Secures $10.9 Million in Series C Financing Round 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Malis CMC-III Generator provides both coagulation and cutting outputs....
Medicine Products: